Biocartis Group (BATS-CHIXE:BCARTB) - Aandelenkoers, Nieuws & Analyse

BCARTB Overzicht aandelen

A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Meer informatie

BCARTB fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 34.34% per jaar groeien

Risicoanalyse

De winst is de afgelopen 5 jaar met 10.5% per jaar gedaald

Negatief eigen vermogen

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

+ 1 meer risico

Biocartis Group NV Concurrenten

Creo Medical Group

AIM:CREO

UK£66.9m

ANGLE

AIM:AGL

UK£33.9m

Ondine Biomedical

AIM:OBI

UK£22.9m

Polarean Imaging

AIM:POLX

UK£18.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Biocartis Group
Historische aandelenkoersen
Huidige aandelenkoers	€1.71
52 Week Hoogtepunt	€3.62
52 Week Laag	€1.71
Bèta	1.7
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-73.01%
5 jaar verandering	-86.40%
Verandering sinds IPO	-74.23%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BCARTB	GB Medical Equipment	GB Markt
7D	0%	-0.4%	2.2%
1Y	n/a	-2.7%	8.0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe BCARTB presteerde ten opzichte van de UK Medical Equipment.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe BCARTB presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is BCARTB's price volatile compared to industry and market?
BCARTB volatility
BCARTB Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: BCARTB heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van BCARTB in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	619	Herman Verrelst	www.biocartisgroupnv.be

Biocartis Group NV Samenvatting

Hoe verhouden de winst en inkomsten van Biocartis Group zich tot de beurswaarde?
BCARTB fundamentele statistieken
Marktkapitalisatie	€68.35m
Inkomsten(TTM)	-€62.96m
Inkomsten(TTM)	€58.61m

1.2x

P/S-verhouding

-1.1x

Koers/Winstverhouding

Is BCARTB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BCARTB resultatenrekening (TTM)
Inkomsten	€58.61m
Kosten van inkomsten	€73.13m
Brutowinst	-€14.52m
Overige uitgaven	€48.45m
Inkomsten	-€62.96m

Laatst gerapporteerde inkomsten

Jun 30, 2022

Volgende inkomensdatum

Nov 10, 2022

Winst per aandeel (EPS)	-1.08
Brutomarge	-24.77%
Nettowinstmarge	-107.42%
Schuld/Eigen Vermogen Verhouding	-209.9%

Hoe presteerde BCARTB op de lange termijn?

Bekijk historische prestaties en vergelijking

BCARTB Overzicht aandelen

Beloningen

Risicoanalyse

Biocartis Group NV Concurrenten

AIM:CREO

UK£66.9m

AIM:AGL

UK£33.9m

AIM:OBI

UK£22.9m

AIM:POLX

UK£18.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Insufficient new directors

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Insufficient new directors

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Insufficient new directors

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Biocartis Group NV Samenvatting

1.2x

-1.1x

Inkomsten en omzet